PJSC Pharmsynthez has reported that it has started the registration phase of Epolong (erythropoietin and polysialic acid conjugate) by filing a registration dossier to obtain approval of Epolong in Russia for the treatment of anemia in patients with chronic kidney disease. The registration dossier is based on previously reported data from Pharmsynthez’s Phase 3 clinical trials of Epolong in Russia, which reportedly demonstrated the efficacy of Epolong and its potential to reduce side effects. Pharmsynthez is leveraging Xenetic’s PolyXen technology to improve the pharmacological properties of its Epolong product candidate pursuant to a royalty-bearing collaboration agreement between the company’s Lipoxen Technologies Limited, and Pharmsynthez’s SynBio LLC.